PharmaLectures.com

Courses › Pharma training by line of business › Week one at the biologics and biosimilars maker: the company, the industry and Europe

Week one at the biologics and biosimilars maker: the company, the industry and Europe

Your new biologics hires file European dossiers right the first time.

  • 10 audio modulesthree lengths each
  • 1 h 40 min to 8 h 20 minbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Biologics and biosimilarswho it is written for

Why this training matters

A new hire reads the Module 3 requirements for a biosimilar the wrong way, and the dossier goes in. The regulator sends back a list of questions, and answering them takes months. Your launch date moves, and a competitor wins the hospital tenders you planned for.

What changes after this course

Your new hires know which route, which document and which regulation applies before they start drafting. Each module ends with a recorded multiple-choice questionnaire. You hold a certificate for every learner and a training record for each person.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your new hire stops asking who owns what. They know which department handles a biologic at each stage, and they read the pipeline and the competitor field before the first project meeting. When a project moves from development to manufacturing, they can say why a monoclonal antibody grown in living cells needs controls a tablet never did.

Regulatory associates settle the route question on the spot. Directive 2001/83/EC and Regulation (EC) No 726/2004 tell them whether the European Medicines Agency or a national authority takes the file. In the plant, quality staff point to EudraLex Volume 4, Annex 1 and Annex 2, and a deviation on the sterile line becomes a documented decision instead of an argument with production.

The Clinical Trial Application goes in complete under Regulation (EU) No 536/2014, with the ethics committee's likely questions already answered in the protocol. Module 3 of the Common Technical Document arrives with sections 3.2.S and 3.2.P filled in the order a reviewer expects. The Risk Management Plan is drafted in the shape the Pharmacovigilance Risk Assessment Committee reads.

Commercial analysts date a launch from the real data exclusivity and market protection periods and from the Supplementary Protection Certificate, not from a guess about patent expiry. When the inspector arrives, facility managers answer Good Manufacturing Practice questions in plain words and write a corrective and preventive action plan the inspector can close.

Who needs this training

  • Regulatory Affairs Associate

    Assembling the Module 3 Quality section for a first European filing, they know where each drug substance and drug product answer belongs, so validation does not return the file with missing items.

  • Clinical Development Manager

    Preparing a Clinical Trial Application under Regulation (EU) No 536/2014, they check the file against the required documents and the ethics committee's questions before submission, not after a request for information.

  • Quality Assurance Specialist

    Facing a production lead who wants to proceed on the sterile line, they cite EudraLex Volume 4, Annex 1, and have a documented risk assessment ready before the batch is held.

  • Commercial Strategy Analyst

    Building a launch timeline for a biosimilar, they work from the real data exclusivity and market protection dates and the Supplementary Protection Certificate, so the date holds in front of the board.

  • Pharmacovigilance Officer

    When a safety signal appears in post-market data, they know who to tell, in what order, and how the Risk Management Plan changes as a result.

Roles: every role in the company

Businesses: Biologics and biosimilars

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. List the documents a European Clinical Trial Application needs under Regulation (EU) No 536/2014 and check a draft file against them.
  2. Name three differences between making a small molecule tablet and producing a monoclonal antibody in living cells.
  3. Decide whether a medicine goes through the centralized procedure or a national route, and cite the regulation that says so.
  4. Place the right content in sections 3.2.S and 3.2.P of Module 3 of the Common Technical Document.
  5. Draft the safety specification of a Risk Management Plan and describe how immunogenicity is monitored.
  6. Work out the earliest filing and launch dates a competitor faces from data exclusivity, market protection and a Supplementary Protection Certificate.
  7. Write a corrective and preventive action plan in reply to an inspection observation.

What the company gets

  • A batch is held less often because quality staff apply EudraLex Volume 4 to the sterile line before the deviation, not after it.
  • Your regulatory team files Module 3 of the Common Technical Document in the order reviewers expect, so fewer questions come back.
  • Inspectors get plain, consistent answers from staff who know their own Good Manufacturing Practice responsibilities.
  • Launch dates rest on real data exclusivity, market protection and Supplementary Protection Certificate dates that the commercial team can defend.
  • You hold a certificate per learner and a training record per person to show an inspector or auditor.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 10 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h 40 min10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard4 h 10 min25 min a module, for regulatory, quality and business-development staff
Expanded8 h 20 min50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing1 h 40 min
Business development and export salesBriefing1 h 40 min
Finance, pricing and tendersBriefing1 h 40 min
Marketing and communicationsBriefing1 h 40 min
Human resources and onboardingBriefing1 h 40 min
IT, data and validationBriefing1 h 40 min
Regulatory affairsStandard4 h 10 min
Quality assurance and Qualified PersonStandard4 h 10 min
Quality control and laboratoryStandard4 h 10 min
Production and engineeringStandard4 h 10 min
Supply chain, purchasing and logisticsStandard4 h 10 min
Pharmacovigilance and medicalStandard4 h 10 min

Course outline: 10 modules

10 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Map who owns what in your company and where each biologic stands

    • Who to call, by department, when a batch, dossier or safety question about your biologic lands on your desk.
    • How to read the pipeline and tell which products are in development, filed or already on the market.
    • What your company's pipeline tells you about which projects your own work will touch next year.
  2. 2Size up the competitors in the global biologics and biosimilars market

    • How to name the rivals who will bid against your biosimilar at the next hospital tender.
    • Why some countries switch patients to biosimilars faster than others, and what that does to a launch plan.
    • Where to find the current market size for your product class so your forecast survives the first question.
  3. 3Spot where biologics manufacturing departs from small molecule making

    • Why a living cell line makes batches vary, and what that changes in your release testing.
    • What a comparability exercise asks of you when a manufacturing change touches an approved biologic.
    • How to explain why a biosimilar is shown to be highly similar, not identical, without losing the room.
  4. 4Apply Directive 2001/83/EC to pick the right European route

    • When a product must go through the centralized procedure under Regulation (EC) No 726/2004, and when not.
    • Which articles of Directive 2001/83/EC answer the question your manager asks you on Monday morning.
    • What to do when a national authority and the European Medicines Agency seem to point in different directions.
  5. 5Implement EudraLex Volume 4 Good Manufacturing Practices for biologics

    • How Annex 1 and Annex 2 of EudraLex Volume 4 change the questions you ask on the sterile line.
    • The quality risk management step that turns a deviation from a held batch into a documented decision.
    • How to keep Chapter 4 records so the Qualified Person can release a batch without sending it back.
  6. 6Plan biologics clinical development and file a Clinical Trial Application

    • The documents Regulation (EU) No 536/2014 expects in a Clinical Trial Application, checked before upload.
    • How to shape phase one to phase three for a biologic whose dose and immune response differ from a pill.
    • What an ethics committee reads first in your protocol, and the gap that gets it sent back.
  7. 7Draft Module 3 of the Common Technical Document for European submissions

    • How to lay out sections 3.2.S and 3.2.P of Module 3 so a reviewer finds each answer at once.
    • What the Quality section must show for a biosimilar so the reviewing committee does not ask twice.
    • How to catch a missing batch analysis table before validation catches it for you.
  8. 8Build a Risk Management Plan for European biologics pharmacovigilance

    • How to build a Risk Management Plan that starts from the safety specification and ends in actions.
    • Why immunogenicity belongs in your Risk Management Plan, and how to word it for reviewers.
    • What to do when a safety signal appears in post-market data, from the first email to regulator contact.
  9. 9Secure market access and intellectual property protection in Europe

    • How data exclusivity and market protection decide when a rival can file and when it can sell.
    • How a Supplementary Protection Certificate extends patent life, and where that extension stops.
    • Why national pricing and reimbursement, not the authorization, set your country launch order.
  10. 10Answer inspector questions during a European biologics compliance audit

    • What an inspector reads before arriving, and how to have the same documents open in the room.
    • How to write a corrective and preventive action plan that an inspector can close without a return visit.
    • The answer that turns a short question into an hour of follow-ups, and the plain reply that stops it.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

10 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h 40 min in the briefing length and 8 h 20 min in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 90 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team